|
| Tuesday, February 11, 2020 |
|
|
知临集团宣布其用于治疗由金黄色葡萄球菌所引起的感染的ALS-4小分子抗毒力（非杀菌）候选药物的进一步正面资料，并可望于2020年下半年提交IND |
| 致力于开发创新疗法以解决全球未被满足的医疗需求的生物制药公司知临集团（那斯达克股票代码：APM），公布其正进行的ALS-4试验用新药（IND）筹备研究的进一步正面资料，该药物采用一种新创新的抗毒力而非杀菌方法 more info >> |
|
|
知臨集團宣布其用於治療由金黃色葡萄球菌所引起的感染的ALS-4小分子抗毒力（非殺菌）候選藥物的進一步正面資料，並可望於2020年下半年提交IND |
| 致力於開發創新療法以解決全球未被滿足的醫療需求的生物製藥公司知臨集團（那斯達克股票代碼：APM），公布其正進行的ALS-4試驗用新藥（IND）籌備研究的進一步正面資料，該藥物採用一種新創新的抗毒力而非殺菌方法 more info >> |
|
|
知临集团宣布用于神经母细胞瘤的再利用候选药物SACT-1取得显著进展并计划2020下半年提交IND |
| 致力于开发创新疗法以解决全球未被满足的医疗需求的生物制药公司知临集团（那斯达克股票代码：APM），宣布其再利用候选药物SACT-1相关的积极数据和开发进展，该药物用于治疗婴幼儿中的罕见儿童癌症——神经母细胞瘤。 more info >> |
|
|
知臨集團宣布用於神經母細胞瘤的再利用候選藥物SACT-1取得顯著進展並計畫2020下半年提交IND |
| 致力於開發創新療法以解決全球未被滿足的醫療需求的生物製藥公司知臨集團（那斯達克股票代碼：APM），宣布其再利用候選藥物SACT-1相關的積極資料和開發進展，該藥物用於治療嬰幼兒中的罕見兒童癌症——神經母細胞瘤。 more info >> |
|
|
Aptorum Group Announces Further Positive Data for its ALS-4 Small Molecule Anti-virulence (Non-bactericidal) Drug Candidate for Treatment of Infections caused by Staphylococcus Aureus |
| Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group"), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, announces further positive data from its current investigational new drug (IND)-enabling studies for ALS-4 more info >> |
|
| Monday, February 10, 2020 |
|
|
Aptorum Group Announces Significant Progress of Repurposed Drug Candidate, SACT-1 for Neuroblastoma Targeting IND Submission in H2 2020 |
| Aptorum Group Limited (Nasdaq: APM) ("Aptorum Group"), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, announces positive data and development in relation to its repurposed drug candidate, SACT-1, for the treatment of neuroblastoma more info >> |
|
| Tuesday, September 10, 2019 |
|
|
知臨集團已啟動用於治療包括MRSA的金黃色葡萄球菌感染小分子候選藥物ALS-4的IND籌備研究 |
知臨集團（納斯達克股票代碼：APM），一家專注於開發新療法以解決全球未被滿足的醫療需求的生物製藥公司，宣布其已啟動針對ALS-4的研究性新藥（IND）籌備研究。 ALS-4是一種小藥物分子候選物，基於新的抗毒力方法以治療由金黃色葡萄球菌包括耐甲氧西林金黃色葡萄球菌（MRSA，即眾所周知的“超級細菌”之一）所引起的感染。
more info >> |
|
|
Aptorum Group has initiated IND-Enabling Studies for its ALS-4 Small Molecule Candidate for the Treatment of Infections Caused by Staphylococcus Aureus including MRSA |
| Aptorum Group Limited (Nasdaq: APM) ("Aptorum Group"), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, announces that it has initiated investigational new drug (IND)-enabling studies for ALS-4 more info >> |
|
|
知臨集團宣布靶向肥胖症微生物組候選藥物和神經母細胞瘤再利用候選藥物的開發 |
知臨集團（納斯達克股票代碼：APM），一家專注於開發新療法以解決全球未竟醫療需求的生物製藥公司，宣布兩個臨床前候選藥物的開發，分別針對肥胖和神經母細胞瘤。
more info >> |
|
|
Aptorum Group Announces the Development of Microbiome Drug Candidate Targeting Obesity and Repurposed Drug Candidates Targeting Neuroblastoma |
Aptorum Group Limited (Nasdaq: APM) ("Aptorum Group"), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, announces the development of two preclinical drug candidates which target obesity and neuroblastoma, respectively.
more info >> |
|
|
|
|
